Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Sponsor
Groupe D'Etude des Tumeurs Uro-Genitales
Study ID
NCT00627354
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • etoposide — DRUG
  • mitoxantrone hydrochloride — DRUG
  • prednisone — DRUG
  • vinorelbine tartrate — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, etoposide, and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which drug is more effective in killing tumor cells. PURPOSE: This randomized phase II trial is studying how well mitoxantrone works compared to etoposide or vinorelbine works as second-line therapy in treating patients with metastatic prostate cancer that did not respond to hormone therapy.

Key Dates

Start date
Sep 30, 2006
Status verified
Jul 2009
Primary completion
May 31, 2011

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Primary Outcome Measure

Palliative response rate

Related Studies